Linaclotide — Discount Pricing

Other medications in Digestive Health

• Lubiprostone
• Metoclopramide
• Misoprostol
• Natalizumab
• Obeticholic Acid
• Ondansetron
• Ozanimod
• Pancrelipase

About Linaclotide

Linaclotide is a prescription medication specifically designed to provide relief for individuals suffering from Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC). These conditions can significantly impact daily life, making effective treatment crucial. TheDrugClub aims to make essential medications like linaclotide more accessible and affordable through valuable membership savings.

Living with Irritable Bowel Syndrome with Constipation (IBS-C) or Chronic Idiopathic Constipation (CIC) can be a daily challenge, marked by uncomfortable symptoms such as abdominal pain, bloating, and infrequent, hard stools. Linaclotide offers a targeted approach to managing these conditions, helping patients regain a sense of normalcy and comfort.

What Linaclotide Treats

Linaclotide is approved to treat two primary conditions in adults:

• Irritable Bowel Syndrome with Constipation (IBS-C): This chronic gastrointestinal disorder is characterized by recurrent abdominal pain or discomfort associated with changes in bowel frequency or consistency, predominantly constipation.
• Chronic Idiopathic Constipation (CIC): This refers to long-term constipation that has no identifiable cause, where individuals experience infrequent bowel movements that are often difficult to pass.

By addressing the underlying mechanisms of these conditions, linaclotide helps alleviate the most disruptive symptoms, improving overall quality of life.

How Linaclotide Works

Linaclotide belongs to a class of drugs known as guanylate cyclase-C (GC-C) agonists. When taken

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Linaclotide is approved for (FDA label)

LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 2 years of age and older LINZESS is a guanylate cyclase-C agonist indicated for treatment of: Irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older. ( 1 ) Chronic idiopathic constipation (CIC) in adults. ( 1 ) Functional constipation (FC) in pediatric patients 2 years of age and older. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: May 21, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Linaclotide (FDA label)

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE LINZESS is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.4 )]. WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE See full prescribing information for complete boxed warning. LINZESS is contraindicated in patients less than 2 years of age; in neonatal mice, linaclotide caused deaths due to dehydration. ( 4 , 5.1 , 8.4 )

Source: FDA prescribing information (DailyMed). Set ID: 09beda19-56d6-4a56-afdc-9a77b70b2ef3. SPL document ID: 621456b5-c1a3-48b8-99ac-ccbf8beebf43. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Linaclotide (FDA label)

LINZESS capsules are white to off-white opaque: 72 mcg; gray imprint “FL 72” 145 mcg; gray imprint “FL 145” 290 mcg; gray imprint “FL 290” Capsules: 72 mcg, 145 mcg and 290 mcg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 09beda19-56d6-4a56-afdc-9a77b70b2ef3. SPL document ID: 621456b5-c1a3-48b8-99ac-ccbf8beebf43. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Linaclotide (FDA label)

Most common adverse reactions (≥2%) reported in adult patients with IBS-C or CIC are: diarrhea, abdominal pain, flatulence and abdominal distension. ( 6.1 ) Most common adverse reaction (≥2%) reported in pediatric patients 7 to 17 years of age with IBS-C and 6 to 17 years of age with FC is diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie, Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 09beda19-56d6-4a56-afdc-9a77b70b2ef3. SPL document ID: 621456b5-c1a3-48b8-99ac-ccbf8beebf43. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.